Atractylenolide Ⅰ protects against lipopolysaccharide-induced disseminated intravascular coagulation by anti-inflammatory and anticoagulation effect

Tang, Xiaomei; Liao, Zhi-Kai; Huang, Youwei; Lin, Xiao; Wu, Li

doi:10.1016/j.apjtm.2017.06.007

Cited by 11 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among 131 components in BZ, 17 components meet the screening criteria. For instance, atractylenolide I, II, III (BZ102, OB = 35.21%, Caco-2 = 1.32, DL = 0.15, GI = high; BZ110, OB = 43.54%, Caco-2 = 1.31, DL = 0.15, GI = high; BZ125, OB = 67.29%, Caco-2 = 0.76, DL = 0.17, GI = high) was the quality marker of BZ in Chinese Pharmacopeia (China, 2015 ) and has anti-inflammatory (Ji et al, 2016 ), anticoagulation effect (Tang et al, 2017 ) gastrointestinal repair effects (Song et al, 2017 ); Atractylenolactam (BZ27, OB = 56.48%, Caco-2 = 1.23, DL = 0.15, GI = high) exhibits anti-inflammatory activity (Hoang et al, 2016 ); Biatractylolide (BZ84, OB = 45.96%, Caco-2 = 0.84, DL = 0.81, GI = high) has a neuroprotective effect on glutamate-induced injury in PC12 and SH-SY5Y cells (Zhu et al, 2017 ). Specially, atractylone has been showed to have anti-microbial and anti-inflammatory activities (Sin et al, 1989 ), so it was also regarded to be active components.…”

Section: Resultsmentioning

confidence: 99%

System Pharmacology-Based Strategy to Decode the Synergistic Mechanism of Zhi-zhu Wan for Functional Dyspepsia

et al. 2018

View full text Add to dashboard Cite

Functional dyspepsia (FD) is a widely prevalent gastrointestinal disorder throughout the world, whereas the efficacy of current treatment in the Western countries is limited. As the symptom is equivalent to the traditional Chinese medicine (TCM) term “stuffiness and fullness,” FD can be treated with Zhi-zhu Wan (ZZW) which is a kind of Chinese patent medicine. However, the “multi-component” and “multi-target” feature of Chinese patent medicine makes it challenge to elucidate the potential therapeutic mechanisms of ZZW on FD. Presently, a novel system pharmacology model including pharmacokinetic parameters, pharmacological data, and component contribution score (CS) is constructed to decipher the potential therapeutic mechanism of ZZW on FD. Finally, 61 components with favorable pharmacokinetic profiles and biological activities were obtained through ADME (absorption, distribution, metabolism, and excretion) screening in silico. The related targets of these components are identified by component targeting process followed by GO analysis and pathway enrichment analysis. And systematic analysis found that through acting on the target related to inflammation, gastrointestinal peristalsis, and mental disorder, ZZW plays a synergistic and complementary effect on FD at the pathway level. Furthermore, the component CS showed that 29 components contributed 90.18% of the total CS values of ZZW for the FD treatment, which suggested that the effective therapeutic effects of ZZW for FD are derived from all active components, not a few components. This study proposes the system pharmacology method and discovers the potent combination therapeutic mechanisms of ZZW for FD. This strategy will provide a reference method for other TCM mechanism research.

show abstract

Section: Resultsmentioning

confidence: 99%

System Pharmacology-Based Strategy to Decode the Synergistic Mechanism of Zhi-zhu Wan for Functional Dyspepsia

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In our previous study, we used LC-MS to conduct ZXD quality control analysis ( Chang et al, 2021 ). This analysis, together with a review of relevant pharmacologically active compounds documented in the literature, revealed that alisol A ( Ho et al, 2019 ), alisol A 24-acetate ( Li et al, 2016 ), alisol A 23-acetate ( Lin, 2012 ), 25-anhydroalisol F ( Bi et al, 2017 ), alisol F ( Bi et al, 2017 ), and alisol M 23-acetate ( Xu et al, 2018 ) in ZX and atractylenolide I ( Chao et al, 2016 ; Tang et al, 2017 ), atractylenolide II ( Chao et al, 2016 ), and atractylenolide III ( Song et al, 2017 ) in BZ are highly potent despite not meeting the predictive thresholds of the TCMSP platform (OB ≥ 30% and DL ≥ 0.18). As such, OB and DL alone are not sufficient to predict the active compounds within TCMFs.…”

Section: Discussionmentioning

confidence: 98%

“…BZ contains bioactive triterpenoid, including atractylenolide I, atractylenolide II, atractylenolide III and so forth ( Hoang et al, 2016 ; Liu et al, 2019 ). Several mechanistic studies have found that ZXD, ZX, BZ, and other active derivatives could treat NAFLD through the modulation of insulin, and PI3K/AKT/NF- κ B and PPAR pathways, thereby suppressing inflammation and lowering lipid levels in treated individuals ( Dan et al, 2011 ; Song et al, 2014 ; Li et al, 2016 ; Bi et al, 2017 ; Tang et al, 2017 ; Wu et al, 2018 ). ZXD is a promising complementary therapy for the treatment of NAFLD.…”

Section: Introductionmentioning

confidence: 99%

Integrating Network Pharmacology and RT-qPCR Analysis to Investigate the Mechanisms Underlying ZeXie Decoction-Mediated Treatment of Non-alcoholic Fatty Liver Disease

Zhang

Ruan

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

ZeXie Decoction (ZXD) is a traditional Chinese medicine composed of Alisma orientalis (Sam.) Juzep. and Atractylodes macrocephala Koidz. ZXD has been widely used to treat non-alcoholic fatty liver disease (NAFLD). The mechanistic basis for the pharmacological activity of ZXD, however, remains poorly understood. In this study, we used a network pharmacology approach and investigated the association between ZXD and NAFLD. We identified the active ingredients of ZXD and screened the potential targets of these ingredients, after which a database of relevant NAFLD-related targets were constructed and several enrichment analyses were performed. Furthermore, the ethanol and aqueous extracts of ZXD were prepared and experimental pharmacology validation was conducted using RT-qPCR of the non-alcoholic fatty liver disease (NAFLD) model in Sprague-Dawley (SD) rats. As a result, a herb-compound-target-pathway network model was developed, and HMGCR, SREBP-2, MAPK1, and NF-κBp65 targets were validated. The gene expression results of these four targets were consistent with those of the network pharmacology prediction. Using an integration strategy, we revealed that ZXD could treat NAFLD by targeting HMGCR, SREBP-2, MAPK1, and NF-κBp65.

show abstract

“…Meanwhile, a former research revealed that alisol C monoacetate and alisol B could inhibit LPS-induced inflammatory reaction [ 61 ]. Although it is unclear whether atractylenolide can improve NAFLD, it has a definite anti-inflammatory and antiapoptosis effect [ 62 , 63 ]. Due to complicated components of Chinese herbal medicine, we only identified ten of the main components of DZD.…”

Section: Discussionmentioning

confidence: 99%

Dahuang Zexie Decoction Protects against High‐Fat Diet‐Induced NAFLD by Modulating Gut Microbiota‐Mediated Toll‐Like Receptor 4 Signaling Activation and Loss of Intestinal Barrier

Fang

Sun

Xue

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Increasing evidence suggests that intestinal dysbiosis, intestinal barrier dysfunction, and activated Toll-like receptor 4 (TLR4) signaling play key roles in the pathogenesis of NAFLD. Dahuang Zexie Decoction (DZD) has been verified to be effective for treating NAFLD, but the mechanisms remain unclear. In this study, we investigated the effects of DZD on NAFLD rats and determined whether such effects were associated with change of the gut microbiota, downregulated activity of the TLR4 signaling pathway, and increased expressions of tight junction (TJ) proteins in the gut. Male Sprague Dawley rats were fed high-fat diet (HFD) for 16 weeks to induce NAFLD and then given DZD intervention for 4 weeks. We found that DZD reduced body and liver weights of NAFLD rats, improved serum lipid levels and liver function parameters, and relieved NAFLD. We further found that DZD changed intestinal bacterial communities, inhibited the intestinal TLR4 signaling pathway, and restored the expressions of TJ proteins in the gut. Meanwhile ten potential components of DZD had been identified. These findings suggest that DZD may protects against NAFLD by modulating gut microbiota-mediated TLR4 signaling activation and loss of intestinal barrier. However, further studies are needed to clarify the mechanism by which DZD treats NAFLD.

show abstract

Atractylenolide Ⅰ protects against lipopolysaccharide-induced disseminated intravascular coagulation by anti-inflammatory and anticoagulation effect

Abstract: ATL-Ⅰ has protective effect on LPS-induced DIC, which can elevate the survival rate, reduce organ damage, improve the function of blood coagulation and suppress TNF-α expression by inhibiting the activation of NF-κB signaling pathway.

Cited by 11 publications

References 26 publications

System Pharmacology-Based Strategy to Decode the Synergistic Mechanism of Zhi-zhu Wan for Functional Dyspepsia

System Pharmacology-Based Strategy to Decode the Synergistic Mechanism of Zhi-zhu Wan for Functional Dyspepsia

Integrating Network Pharmacology and RT-qPCR Analysis to Investigate the Mechanisms Underlying ZeXie Decoction-Mediated Treatment of Non-alcoholic Fatty Liver Disease

Dahuang Zexie Decoction Protects against High‐Fat Diet‐Induced NAFLD by Modulating Gut Microbiota‐Mediated Toll‐Like Receptor 4 Signaling Activation and Loss of Intestinal Barrier

Contact Info

Product

Resources

About